secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0001826667-25-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q4 rev $8.3M (+44% YoY), FY2024 rev $29.4M (+59% YoY); guides to positive EBITDA in 2025
--------------------------------------------------------------------------------

- Q4 2024 revenue ~$8.3M, up 44% YoY; FY2024 revenue ~$29.4M, up 59% YoY.
- Q4 operating cash flow (~$5.6M) improved from (~$10.8M) in Q3.
- Expects positive full-year EBITDA in 2025 and positive cash flow during H2 2025.
- Cash ~$8.5M; expects to qualify for additional $10M debt tranche from OrbiMed in Q1 2025.
- Revenue growth guidance for 2025: in excess of 50%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000007/0001826667-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000007/tlsi-20250123.htm
  HTML page:      https://secwatch.observer/filing/0001826667-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer